Brain, Vol. 125, No. 10, 2248-2256,
October 2002
© 2002 Oxford University Press
Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study
1 MRC Clinical Sciences Centre, and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, 2 Neurogenetics Unit, Institute of Neurology and 3 Reta Lila Weston Institute of Neurological Studies, Royal Free Hospital and University College Medical School, London, UK
Correspondence to: P. Piccini, MRC Cyclotron Building, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK E-mail: paola.piccini{at}csc.mrc.ac.uk
Molecular and clinical characterization of parkin-associated parkinsonism is well described; however, there are no data available on progression of dopamine terminal dysfunction in parkin-associated disease. We have used [18F]dopa PET serially to study members of a family with young-onset parkinsonism who are compound heterozygous for mutations in the parkin gene, having an exonic deletion and a novel intronic splice site mutation. Four patients have been studied twice, 10 years apart, to assess disease progression. Additionally, we have studied five asymptomatic family members, four of whom carry a single parkin mutation and one individual who has a normal genotype. Two of the carriers and the individual with the normal genotype had repeat [18F]dopa PET. The group of parkin patients showed a significantly slower loss of putamen [18F]dopa uptake (P = 0.0008) compared with a group of idiopathic Parkinsons disease (IPD) patients who had baseline putamen [18F]dopa uptake and disease severity similar to the parkin group. These results indicate that disease progression in patients with parkin mutations is slower than that of IPD patients. The group of asymptomatic parkin carriers also showed significant striatal dopaminergic dysfunction, and three of them developed subtle extrapyramidal signs. However, the two carriers scanned twice showed no progression over a 7-year period. The slower rate of disease progression in parkin patients may explain the near normal longevity of these patients with young onset parkinsonism.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
B.F.L. van Nuenen, M. M. Weiss, B. R. Bloem, K. Reetz, T. van Eimeren, K. Lohmann, J. Hagenah, P. P. Pramstaller, F. Binkofski, C. Klein, et al. Heterozygous carriers of a Parkin or PINK1 mutation share a common functional endophenotype Neurology, March 24, 2009; 72(12): 1041 - 1047. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Lohmann, S. Thobois, S. Lesage, E. Broussolle, S. T. du Montcel, M. -J. Ribeiro, P. Remy, A. Pelissolo, B. Dubois, L. Mallet, et al. A multidisciplinary study of patients with early-onset PD with and without parkin mutations Neurology, January 13, 2009; 72(2): 110 - 116. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Mizuno, N. Hattori, S.-i. Kubo, S. Sato, K. Nishioka, T. Hatano, H. Tomiyama, M. Funayama, Y. Machida, and H. Mochizuki Progress in the pathogenesis and genetics of Parkinson's disease Phil Trans R Soc B, June 27, 2008; 363(1500): 2215 - 2227. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Baumer, P. P. Pramstaller, H. R. Siebner, S. Schippling, J. Hagenah, M. Peller, C. Gerloff, C. Klein, and A. Munchau Sensorimotor integration is abnormal in asymptomatic Parkin mutation carriers: A TMS study Neurology, November 20, 2007; 69(21): 1976 - 1981. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Binkofski, K. Reetz, C. Gaser, R. Hilker, J. Hagenah, K. Hedrich, T. van Eimeren, A. Thiel, C. Buchel, P. P. Pramstaller, et al. Morphometric fingerprint of asymptomatic Parkin and PINK1 mutation carriers in the basal ganglia Neurology, August 28, 2007; 69(9): 842 - 850. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-K. Sang, H.-Y. Chang, G. M. Lawless, A. Ratnaparkhi, L. Mee, L. C. Ackerson, N. T. Maidment, D. E. Krantz, and G. R. Jackson A Drosophila Model of Mutant Human Parkin-Induced Toxicity Demonstrates Selective Loss of Dopaminergic Neurons and Dependence on Cellular Dopamine J. Neurosci., January 31, 2007; 27(5): 981 - 992. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Linazasoro Rate of progression determines the clinical outcome after neural transplantation in Parkinson's disease. Brain, July 1, 2006; 129(Pt 7): E48 - E48. [Full Text] [PDF] |
||||
![]() |
C. Buhmann, F. Binkofski, C. Klein, C. Buchel, T. van Eimeren, C. Erdmann, K. Hedrich, M. Kasten, J. Hagenah, G. Deuschl, et al. Motor reorganization in asymptomatic carriers of a single mutant Parkin allele: a human model for presymptomatic parkinsonism Brain, October 1, 2005; 128(10): 2281 - 2290. [Abstract] [Full Text] [PDF] |
||||
![]() |
S M Hague, S Klaffke, and O Bandmann Neurodegenerative disorders: Parkinson's disease and Huntington's disease J. Neurol. Neurosurg. Psychiatry, August 1, 2005; 76(8): 1058 - 1063. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Beilina, M. Van Der Brug, R. Ahmad, S. Kesavapany, D. W. Miller, G. A. Petsko, and M. R. Cookson Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability PNAS, April 19, 2005; 102(16): 5703 - 5708. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. L. Khan, C. Scherfler, E. Graham, K. P. Bhatia, N. Quinn, A. J. Lees, D. J. Brooks, N. W. Wood, and P. Piccini Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation Neurology, January 11, 2005; 64(1): 134 - 136. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Varrone, M. T. Pellecchia, M. Amboni, V. Sansone, E. Salvatore, D. Ghezzi, B. Garavaglia, A. Brice, A. Brunetti, V. Bonavita, et al. Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease Neurology, December 14, 2004; 63(11): 2097 - 2103. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Scherfler, N. L. Khan, N. Pavese, L. Eunson, E. Graham, A. J. Lees, N. P. Quinn, N. W. Wood, D. J. Brooks, and P. P. Piccini Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism Brain, June 1, 2004; 127(6): 1332 - 1342. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. L. Khan, R. Katzenschlager, H. Watt, K. P. Bhatia, N. W. Wood, N. Quinn, and A. J. Lees Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease Neurology, April 13, 2004; 62(7): 1224 - 1226. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Baptista, M. R. Cookson, and D. W. Miller Parkin and {alpha}-Synuclein: Opponent Actions in The Pathogenesis of Parkinson'S Disease Neuroscientist, February 1, 2004; 10(1): 63 - 72. [Abstract] [PDF] |
||||
![]() |
M. C. J. Dekker, V. Bonifati, and C. M. van Duijn Parkinson's disease: piecing together a genetic jigsaw Brain, August 1, 2003; 126(8): 1722 - 1733. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. L. Khan, E. Graham, P. Critchley, A. E. Schrag, N. W. Wood, A. J. Lees, K. P. Bhatia, and N. Quinn Parkin disease: a phenotypic study of a large case series Brain, June 1, 2003; 126(6): 1279 - 1292. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Thobois, M.-J. Ribeiro, E. Lohmann, A. Durr, P. Pollak, O. Rascol, S. Guillouet, E. Chapoy, N. Costes, Y. Agid, et al. Young-Onset Parkinson Disease With and Without Parkin Gene Mutations: A Fluorodopa F 18 Positron Emission Tomography Study Arch Neurol, May 1, 2003; 60(5): 713 - 718. [Abstract] [Full Text] [PDF] |
||||







